EP2849720A2 - Use of a chaste tree extract for preparing a cosmetic and/or dermatological composition - Google Patents

Use of a chaste tree extract for preparing a cosmetic and/or dermatological composition

Info

Publication number
EP2849720A2
EP2849720A2 EP13724551.0A EP13724551A EP2849720A2 EP 2849720 A2 EP2849720 A2 EP 2849720A2 EP 13724551 A EP13724551 A EP 13724551A EP 2849720 A2 EP2849720 A2 EP 2849720A2
Authority
EP
European Patent Office
Prior art keywords
composition
extract
chasteberry
use according
cosmetic
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP13724551.0A
Other languages
German (de)
French (fr)
Inventor
Isabelle GARCIN-VOLLE
Dominique Delaunay
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
PANDO
Original Assignee
PANDO
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48483045&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EP2849720(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by PANDO filed Critical PANDO
Publication of EP2849720A2 publication Critical patent/EP2849720A2/en
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/85—Verbenaceae (Verbena family)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
    • A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
    • A61K8/9783—Angiosperms [Magnoliophyta]
    • A61K8/9789—Magnoliopsida [dicotyledons]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin

Definitions

  • Chasteberry extract for the preparation of a cosmetic and / or dermatological composition
  • the present invention relates to the use of a Gattilier extract for the preparation of a cosmetic and / or dermatological composition for stimulating the production of dopamine in cutaneous tissues, as well as a cosmetic and / or dermatological composition comprising said Chasteberry extract.
  • Gattilier is a Mediterranean shrub of the family Verbissecées, mainly represented by the species "Vitex agnus-castus", with small flowers, in whorls spaced, white or bluish, with tubular calyx, with irregular corolla carved of five lobes. Said flowers give berries (fruits), called “pepper monks”. The Gattilier is also well known under the Anglicism "Monk's pepper tree”.
  • EP-1 980 241 is known a wet wipe impregnated with an impregnating liquid, used in the field of feminine hygiene.
  • This impregnating liquid having soothing and calming properties, consists of a dried fruit extract from Vitex agnus-castus.
  • Vitex agnus-castus makes it possible to reduce the level of prolactin thanks to its dopaminergic activity.
  • the purpose of the present invention is to propose, in particular, a new use of a Gattilier extract for the preparation of a composition, in particular a cosmetic and / or dermatological composition.
  • the Chasteberry extract is therefore the main active ingredient of the composition according to the invention.
  • the subject of the present invention is a use of a Chasteberry extract for the preparation of a cosmetic composition and / or Dermatological to stimulate dopamine production of cutaneous tissues, especially in topical application.
  • Dopamine thus secreted at the cutaneous level advantageously plays a major role in maintaining cutaneous permeability and cutaneous homeostasis.
  • composition according to the invention is effective in stimulating the production of dopamine by topical application, and thus improving the state of the cutaneous surface, and the homeostasis of the cutaneous barrier.
  • the extract of Gattilier advantageously protects the skin, especially against external aggressions of the skin, and maintain a healthy and radiant cutaneous appearance.
  • the external aggressions can be of physical type, such as ultraviolet radiation, and / or of chemical type, such as surfactants, solvents such as ethanol, etc.
  • the extract of Gattilier advantageously allows to increase the cellular oxygenation, to improve the nutrition of the skin.
  • the composition according to the invention makes it possible to promote the reconstruction of the barrier function of the stratum corneum thereby improving the homeostasis of the epidermis, the proper functioning of the barrier leading to the improvement of the brightness of the skin. skin.
  • the Chasteberry extract may be in particular an extract of Vitex agnus castus.
  • the Chasteberry extract may be obtained from Chasteberry berries, and particularly preferably, the Chasteberry extract may be a dry extract or a liquid extract, containing in particular casticine.
  • Chasteberry extract comprises an extract of dried berries.
  • composition of the invention it is preferred to use a liquid extract of Chasteberry.
  • the cutaneous tissues of the invention more generally refer to the skin, which consists of both a living anatomical barrier and an exchange zone between the body and its environment, the effectiveness of this barrier conditioning the skin. maintaining a good homeostatic balance. It consists of several layers ranging from the superficial layer, the epidermis, to the deeper layers, the dermis and the hypodermis. Each of these layers has specific properties allowing the whole to react and adapt to the conditions of its environment.
  • the epidermis which is composed of three types of cells, namely keratinocytes (90% of epidermal cells), melanocytes (2 to 3% of epidermal cells) and Langerhans cells, constitutes the outer layer and plays a role. fundamental to ensure the protection and maintenance of good trophicity.
  • the dermis is 10 to 30 times thicker than the epidermis, which it serves as a support, and it is mainly composed of fibroblasts and an extracellular matrix mainly based on collagen and elastin.
  • Collagen fibers which make up about 70% of dermal proteins, contribute to the texture and tone of the skin, while elastin is responsible for its elasticity.
  • Other cells such as macrophages and leucocytes, are also present in the dermis layer.
  • the hypodermis which is the deepest layer of the skin, contains the lipid-producing fat cells so that the subcutaneous tissue makes a fat layer that protects the muscles, bones, and internal organs from shock.
  • the Chasteberry extract can thus act:
  • keratinocytes preferably on normal human keratinocytes, cutaneous tissues, and / or on cutaneous tissue fibroblasts.
  • the composition may be formulated preferably for topical application.
  • the composition of the invention may comprise at most 5% by weight of a Chasteberry extract relative to the total weight of the composition, preferably at most 2% by weight of a Chasteberry extract relative to the total weight of the composition, preferably at most 1% by weight of a Chasteberry extract relative to the total weight of the composition, and preferably at most 0.2% by weight of a Chasteberry extract relative to the total weight of the composition .
  • This upper limit advantageously makes it possible to guarantee the total safety of the composition on the cutaneous tissues, and in particular on the epidermal human cells.
  • composition of the invention may comprise at least 0.006% by weight of a Chasteberry extract relative to the total weight of the composition, and preferably at least 0.02% by weight of a Chasteberry extract relative to the weight total composition
  • This lower limit advantageously makes it possible to guarantee the effectiveness of the composition in stimulating the activity of cutaneous tissues, and in particular keratinocytes, on the production of dopamine.
  • the composition can comprise from 0.006% to 5% by weight of an extract of Chasteberry, relative to the total weight of the composition
  • the composition of the invention may comprise from 0.02% to 1% by weight of a Chasteberry extract relative to the total weight of the composition.
  • the Chasteberry extract in the composition of the invention is preferably a liquid extract.
  • Said liquid extract can be obtained according to the following conventional extraction method:
  • Chasteberry berries including crushed Chasteberry berries, in a solvent, such as alcohol (eg ethanol), water, or a mixture of water and alcohol (eg example a mixture of water and ethanol),
  • a solvent such as alcohol (eg ethanol), water, or a mixture of water and alcohol (eg example a mixture of water and ethanol),
  • Said method may comprise a washing step, prior to the extraction step.
  • This washing step may be a step of washing the Chasteberry berries in a solvent such as alcohol (eg ethanol), water, or a mixture of water and alcohol (eg example a mixture of water and ethanol); and then filtering the liquid residue (i.e. the washing solvent) to obtain washed chasteberry berries.
  • a solvent such as alcohol (eg ethanol), water, or a mixture of water and alcohol (eg example a mixture of water and ethanol); and then filtering the liquid residue (i.e. the washing solvent) to obtain washed chasteberry berries.
  • Said method may further comprise steps well known to those skilled in the art after the residue filtration step, such as by for example, a purification step by filtration of the liquid extract of Chasteberry.
  • the liquid extract of Chasteberry can be more or less diluted in a solvent such as alcohol (for example ethanol), water, or a mixture of water and alcohol (for example a mixture of water and ethanol), according to the needs of the composition according to the invention.
  • a solvent of the water / alcohol mixture type mainly comprising water, and preferably 60-70% of water for 40-30%. alcohol (volume to volume).
  • the composition of the invention may further comprise a first encapsulation vector, intended to encapsulate the Chasteberry extract.
  • said first encapsulation vector may be a cyclodextrin.
  • composition may further comprise a second encapsulation vector for encapsulating said first encapsulation vector.
  • said second encapsulation vector may be a liposome, such as in particular lecithin.
  • compositions in accordance with the present invention may be presented in the forms conventionally used for topical application, that is to say in the form of a gel, lotion, emulsion (in particular cream or milk), serum (or essence), mask or ointment, containing compatible and pharmaceutically acceptable excipients and common carriers. They may also be in the form of wipes soaked with a solution containing Chasteberry extract according to the invention.
  • Topical administration are prepared by techniques well known to those skilled in the art, and for example, in the case of a cream, by dispersion of a fatty phase in an aqueous phase to obtain an oil emulsion. in water, or conversely to prepare a water-in-oil emulsion.
  • composition according to the invention may comprise one or more usual excipients, particularly suitable for external topical administration, in particular dermatologically and cosmetologically acceptable excipients.
  • excipients suitable for the formulation are well known to those skilled in the art, and may be chosen for example from one or more of the compounds i to xvi listed below:
  • antioxidant vitamins such as vitamin E, for example tocopherol acetate or tocotrienol; vitamin C, for example ascorbyl tetraisopalmitate; natural polyphenols;
  • vectors of active ingredients such as cyclodextrins; liposomes, for example lecithin;
  • gelling agents and / or thickeners such as natural gums; synthetic polymers;
  • emulsifiers and co-emulsifiers such as arachidyl glucoside; cetearyl glucoside; behenyl alcohol; cetearyl alcohol; cetostearyl alcohol; cetearyl alcohol; cetyl alcohol, steareth-2; steareth-21; isostearyl isostearate; isopropyl myristate;
  • emollients and surfactants such as octyl dodecanol; isononyl isononanoate; capric / caprylic triglycerides; cetearyl octanoate; isopropyl myristate; cetearyl isononanoate; polyglyceryl 3-diisostearate; hydrogenated polyisobutene; cetyl palmitate; cetyl phosphate;
  • silicones such as dimethicone, cyclomethicone
  • humectants / moisturizers such as glycerine; butylene glycol; propylene glycol;
  • preservatives such as phenoxyethanol, dehydroacetic acid; benzoic acid; potassium sorbate; sodium benzoate; methyl, ethyl, propyl, butyl and isobutyl parahydroxybenzoates;
  • agents for protecting against ultraviolet rays such as hydrophilic or lipophilic UV-A and UV-B sunscreens, chosen from benzophenone or a benzophenone derivative such as 2-hydroxy-4-methoxybenzophenone; a cinnamic acid ester; and more particularly octyl methoxycinnamate, 2-ethylhexyl methoxycinnamate, or a cyano- ⁇ , ⁇ -diphenylacrylate such as octo-crylene, 4-methylbenzylidene camphor, and dibenzoylmethane derivatives such as 4-isopropyl dibenzoylmethane, t-butyl-methoxy dibenzoylmethane, and 4-methoxy-dibenzoylmethane, or such as UV screen-forming pigments. exfoliating powders; fruit powders; or mattifying powders such as methyl methacrylate copolymer;
  • composition according to the invention may further comprise one or more usual complementary active agents, especially adapted for external topical administration, in particular dermatologically and cosmetologically acceptable active ingredients.
  • complementary active agents suitable for the formulation are well known to those skilled in the art, and may be, for example, anti-aging active agents, soothing active agents, purifying active agents, slimming active agents, moisturizing active agents, etc.
  • composition of the invention may comprise, in addition to the Chasteberry extract, one or more antioxidant vitamins, such as, for example, ascorbyl tetraisopalmitate and / or tocopherol.
  • antioxidant vitamins such as, for example, ascorbyl tetraisopalmitate and / or tocopherol.
  • the Chasteberry extract is vectorized, by nanoemulsion, in order to be able to more easily control the release of Chasteberry extract, and improve its bioavailability.
  • the Chasteberry extract may be encapsulated in a first vector, such as cyclodextrins.
  • a first vector such as cyclodextrins.
  • the Chasteberry extract may itself be encapsulated in a second vector, such as liposomes such as lecithin.
  • FIG. 1 represents a diagram of the keratinocyte production of dopamine after 24 hours of incubation in the presence of a control, and in the presence of formulations comprising a Chasteberry extract.
  • a commercially available formulation was used to evaluate the effect of Chasteberry extract on the production of dopamine from normal human keratinocytes in cultures.
  • This formulation is the product referenced "Happybelle-PE”, marketed by Mibelle AG Biochemistry.
  • This formulation includes:
  • a liquid extract of Vitex agnus-castus berries such as Chasteberry extract
  • this liquid extract is based on a solvent comprising a mixture of water and ethanol (70/30 volume to volume), said liquid extract comprising 0.3% by weight of dry extract of berries
  • Chasteberry liquid extract in this formulation is about 12.5% by weight based on the total weight of the formulation.
  • normal human keratinocytes were obtained from an abdominal plasty carried out in a 66-year-old woman.
  • the keratinocytes were then incubated for 24 hours at 37 ° C. under a humid atmosphere and 5% CO 2 .
  • control in the culture medium in the presence of a reference product (i.e. control),
  • the culture medium alone is an "untreated” medium, which does not include any reference product or "Happybelle-PE” formulation.
  • the reference product or in other words the control, is amantadine hydrochloride 0.1 ⁇ .
  • the dopamine contained in the explant incubation media was quantified using an E.I.A. kit. ("Enzyme Immuno Assay”) sensitive and specific.
  • FIG. 1 shows the keratinocyte production of dopamine as a percentage relative to the control (100%):
  • the formulation "Happybelle-PE” is thus capable of significantly increasing the production of dopamine of normal human keratinocytes in culture.
  • dopamine production of normal human keratinocytes in culture is: - 6.1 times greater than that of the control, for the formulation "Happybelle-PE” at 0.01% (v / v), and
  • amantadine hydrochloride used as a control, induced keratinocyte production of dopamine 5 times greater than that of cells in culture medium alone. Obtaining this result is considered sufficient to validate the study.
  • composition according to the invention is effective for obtaining dopamine production by topical application, and thus improving the state of the cutaneous surface and the homeostasis of the cutaneous barrier. As a result, the skin is better protected, and the complexion more radiant.
  • the product referenced "Happybelle-PE”, marketed by the company Mibelle AG Biochemistry, comprises about 12.5% by weight of liquid extract of Chasteberry (relative to the total weight of the product Happybelle-PE ).
  • composition according to the invention having the following weight composition is prepared:

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Dermatology (AREA)
  • Medical Informatics (AREA)
  • Birds (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cosmetics (AREA)

Abstract

The present invention relates to a use of a chaste tree extract for preparing a cosmetic and/or dermatological composition to stimulate dopamine production in skin tissue.

Description

Utilisation d'un extrait de Gattilier pour la préparation d'une composition cosmétique et/ou dermatologique  Use of a Chasteberry extract for the preparation of a cosmetic and / or dermatological composition
La présente invention se rapporte à l'utilisation d'un extrait de Gattilier pour la préparation d'une composition cosmétique et/ou dermatologique pour stimuler la production de dopamine des tissus cutanés, ainsi qu'à une composition cosmétique et/ou dermatologique comprenant ledit extrait de Gattilier. The present invention relates to the use of a Gattilier extract for the preparation of a cosmetic and / or dermatological composition for stimulating the production of dopamine in cutaneous tissues, as well as a cosmetic and / or dermatological composition comprising said Chasteberry extract.
Le Gattilier est un arbrisseau méditerranéen de la famille des Verbénacées, principalement représenté par l'espèce « Vitex agnus-castus », aux fleurs petites, en verticilles espacés, blanches ou bleuâtres, à calice tubuleux, à corolle irrégulière découpée de cinq lobes. Lesdites fleurs donnent des baies (fruits), appelées « poivre des moines ». Le Gattilier est d'ailleurs bien connu sous l'anglicisme « Monk's pepper tree ».  Gattilier is a Mediterranean shrub of the family Verbénacées, mainly represented by the species "Vitex agnus-castus", with small flowers, in whorls spaced, white or bluish, with tubular calyx, with irregular corolla carved of five lobes. Said flowers give berries (fruits), called "pepper monks". The Gattilier is also well known under the Anglicism "Monk's pepper tree".
Du document EP-1 980 241 est connue une lingette humide imprégnée par un liquide d'imprégnation, utilisée dans le domaine de l'hygiène féminin. Ce liquide d'imprégnation, ayant des propriétés apaisantes et calmantes, se compose d'un extrait de fruits séchés issus du Vitex agnus-castus.  From EP-1 980 241 is known a wet wipe impregnated with an impregnating liquid, used in the field of feminine hygiene. This impregnating liquid, having soothing and calming properties, consists of a dried fruit extract from Vitex agnus-castus.
L'effet dopaminergique du Vitex agnus-castus est bien connu de ce document. Le Vitex agnus-castus permet ainsi de diminuer le niveau de prolactine grâce à son activité dopaminergique.  The dopaminergic effect of Vitex agnus-castus is well known from this document. Vitex agnus-castus thus makes it possible to reduce the level of prolactin thanks to its dopaminergic activity.
Cependant, malgré les diverses compositions dermatologiques et/ou cosmétiques disponibles, il existe toujours un besoin de pouvoir disposer de nouvelles compositions alternatives ayant de nouveaux effets bénéfiques liés à l'effet dopaminergique. A ce titre, une nouvelle application d'un extrait de Gattilier a été découverte par la Demanderesse.  However, despite the various dermatological and / or cosmetic compositions available, there is still a need to be able to have new alternative compositions having new beneficial effects related to the dopaminergic effect. As such, a new application of a Gattilier extract has been discovered by the Applicant.
Le but de la présente invention est de proposer notamment une nouvelle utilisation d'un extrait de Gattilier pour la préparation d'une composition, notamment d'une composition cosmétique et/ou dermatologique.  The purpose of the present invention is to propose, in particular, a new use of a Gattilier extract for the preparation of a composition, in particular a cosmetic and / or dermatological composition.
L'extrait de Gattilier est donc l'actif principal de la composition selon l'invention.  The Chasteberry extract is therefore the main active ingredient of the composition according to the invention.
Ainsi, la présente invention a pour objet une utilisation d'un extrait de Gattilier pour la préparation d'une composition cosmétique et/ou dermatologique pour stimuler la production de dopamine des tissus cutanés, notamment en application topique. Thus, the subject of the present invention is a use of a Chasteberry extract for the preparation of a cosmetic composition and / or Dermatological to stimulate dopamine production of cutaneous tissues, especially in topical application.
La dopamine ainsi sécrétée au niveau cutané joue avantageusement un rôle majeur dans le maintien de la perméabilité cutanée et de l'homéostasie cutanée.  Dopamine thus secreted at the cutaneous level advantageously plays a major role in maintaining cutaneous permeability and cutaneous homeostasis.
Ainsi, la composition selon l'invention est efficace pour stimuler la production de dopamine par application topique, et ainsi améliorer l'état de la surface cutanée, et l'homéostasie de la barrière cutanée.  Thus, the composition according to the invention is effective in stimulating the production of dopamine by topical application, and thus improving the state of the cutaneous surface, and the homeostasis of the cutaneous barrier.
Par conséquent, l'extrait de Gattilier permet avantageusement de protéger la peau, notamment contre les agressions extérieures de la peau, et de maintenir une apparence cutanée saine et radieuse. Les agressions extérieures peuvent être de type physique, comme par exemple les rayonnements ultra-violets, et/ou de type chimique, comme par exemple les tensio-actifs, les solvants tels que l'éthanol, ...etc. En outre, l'extrait de Gattilier permet avantageusement d'accroître l'oxygénation cellulaire, afin d'améliorer la nutrition de la peau.  Therefore, the extract of Gattilier advantageously protects the skin, especially against external aggressions of the skin, and maintain a healthy and radiant cutaneous appearance. The external aggressions can be of physical type, such as ultraviolet radiation, and / or of chemical type, such as surfactants, solvents such as ethanol, etc. In addition, the extract of Gattilier advantageously allows to increase the cellular oxygenation, to improve the nutrition of the skin.
De ce fait, la composition selon l'invention permet de favoriser la reconstruction de la fonction barrière de la couche cornée améliorant ainsi l'homéostasie de l'épiderme, le bon fonctionnement de la barrière conduisant à l'amélioration de l'éclat de la peau.  As a result, the composition according to the invention makes it possible to promote the reconstruction of the barrier function of the stratum corneum thereby improving the homeostasis of the epidermis, the proper functioning of the barrier leading to the improvement of the brightness of the skin. skin.
L'extrait de Gattilier peut être notamment un extrait de Vitex agnus- castus.  The Chasteberry extract may be in particular an extract of Vitex agnus castus.
De préférence, l'extrait de Gattilier peut être obtenu à partir des baies de Gattilier, et de façon particulièrement préférée, l'extrait de Gattilier peut être un extrait sec ou un extrait liquide, contenant notamment de la casticine.  Preferably, the Chasteberry extract may be obtained from Chasteberry berries, and particularly preferably, the Chasteberry extract may be a dry extract or a liquid extract, containing in particular casticine.
De façon particulièrement préférée, l'extrait de Gattilier comprend un extrait de baies séchées.  In a particularly preferred manner, Chasteberry extract comprises an extract of dried berries.
Dans la composition de l'invention, on préférera utiliser un extrait liquide de Gattilier.  In the composition of the invention, it is preferred to use a liquid extract of Chasteberry.
Les tissus cutanés de l'invention font référence plus généralement à la peau, qui est constituée à la fois d'une barrière anatomique vivante et d'une zone d'échange entre le corps et son environnement, l'efficacité de cette barrière conditionnant le maintien d'un bon équilibre homéostasique. Elle comprend plusieurs couches allant de la couche superficielle, répiderme, aux couches plus profondes, le derme et l'hypoderme. Chacune de ces couches possède des propriétés spécifiques permettant à l'ensemble de réagir et de s'adapter aux conditions de son environnement. The cutaneous tissues of the invention more generally refer to the skin, which consists of both a living anatomical barrier and an exchange zone between the body and its environment, the effectiveness of this barrier conditioning the skin. maintaining a good homeostatic balance. It consists of several layers ranging from the superficial layer, the epidermis, to the deeper layers, the dermis and the hypodermis. Each of these layers has specific properties allowing the whole to react and adapt to the conditions of its environment.
L'épiderme, qui est composé de trois types de cellules, à savoir des kératinocytes (90 % des cellules épidermiques), des mélanocytes (2 à 3 % des cellules épidermiques) et des cellules de Langerhans, constitue la couche externe et joue un rôle fondamental pour assurer la protection et le maintien d'une bonne trophicité.  The epidermis, which is composed of three types of cells, namely keratinocytes (90% of epidermal cells), melanocytes (2 to 3% of epidermal cells) and Langerhans cells, constitutes the outer layer and plays a role. fundamental to ensure the protection and maintenance of good trophicity.
Le derme est 10 à 30 fois plus épais que l'épiderme, auquel il sert de support, et il est principalement constitué de fibroblastes et d'une matrice extracellulaire essentiellement à base de collagène et d'élastine. Les fibres de collagène, qui représentent environ 70 % des protéines du derme, contribuent à la texture et à la tonicité de la peau, tandis que l'élastine est responsable de son élasticité. D'autres cellules, comme les macrophages et les leucocytes, sont également présentes dans la couche du derme.  The dermis is 10 to 30 times thicker than the epidermis, which it serves as a support, and it is mainly composed of fibroblasts and an extracellular matrix mainly based on collagen and elastin. Collagen fibers, which make up about 70% of dermal proteins, contribute to the texture and tone of the skin, while elastin is responsible for its elasticity. Other cells, such as macrophages and leucocytes, are also present in the dermis layer.
L'hypoderme, qui est la couche la plus profonde de la peau, contient les adipocytes qui produisent des lipides pour que le tissu sous-cutané fabrique une couche grasse protégeant les muscles, les os, et les organes internes contre les chocs.  The hypodermis, which is the deepest layer of the skin, contains the lipid-producing fat cells so that the subcutaneous tissue makes a fat layer that protects the muscles, bones, and internal organs from shock.
Dans la présente invention, l'extrait de Gattilier peut ainsi agir :  In the present invention, the Chasteberry extract can thus act:
sur les kératinocytes, de préférences sur les kératinocytes humains normaux, des tissus cutanés, et/ou sur les fibroblastes des tissus cutanés.  on keratinocytes, preferably on normal human keratinocytes, cutaneous tissues, and / or on cutaneous tissue fibroblasts.
Suivant l'invention, la composition peut être formulée de préférence pour une application topique.  According to the invention, the composition may be formulated preferably for topical application.
La composition de l'invention peut comprendre au plus 5 % en poids d'un extrait de Gattilier par rapport au poids total de la composition, de préférence au plus 2 % en poids d'un extrait de Gattilier par rapport au poids total de la composition, de préférence au plus 1 % en poids d'un extrait de Gattilier par rapport au poids total de la composition, et de préférence au plus 0,2 % en poids d'un extrait de Gattilier par rapport au poids total de la composition. Cette limite supérieure permet avantageusement de garantir la totale innocuité de la composition sur les tissus cutanés, et notamment sur les cellules humaines épidermiques. The composition of the invention may comprise at most 5% by weight of a Chasteberry extract relative to the total weight of the composition, preferably at most 2% by weight of a Chasteberry extract relative to the total weight of the composition, preferably at most 1% by weight of a Chasteberry extract relative to the total weight of the composition, and preferably at most 0.2% by weight of a Chasteberry extract relative to the total weight of the composition . This upper limit advantageously makes it possible to guarantee the total safety of the composition on the cutaneous tissues, and in particular on the epidermal human cells.
La composition de l'invention peut comprendre au moins 0,006 % en poids d'un extrait de Gattilier par rapport au poids total de la composition, et de préférence au moins 0,02 % en poids d'un extrait de Gattilier par rapport au poids total de la composition  The composition of the invention may comprise at least 0.006% by weight of a Chasteberry extract relative to the total weight of the composition, and preferably at least 0.02% by weight of a Chasteberry extract relative to the weight total composition
Cette limite inférieure permet avantageusement de garantir l'efficacité de la composition sur la stimulation de l'activité des tissus cutanés, et notamment des kératinocytes, sur la production de dopamine.  This lower limit advantageously makes it possible to guarantee the effectiveness of the composition in stimulating the activity of cutaneous tissues, and in particular keratinocytes, on the production of dopamine.
De ce fait, la composition peut comprendre de 0,006 % à 5 % en poids d'un extrait de Gattilier, par rapport au poids total de la composition  As a result, the composition can comprise from 0.006% to 5% by weight of an extract of Chasteberry, relative to the total weight of the composition
De préférence, la composition de l'invention peut comprendre de 0,02 % à 1 % en poids d'un extrait de Gattilier par rapport au poids total de la composition.  Preferably, the composition of the invention may comprise from 0.02% to 1% by weight of a Chasteberry extract relative to the total weight of the composition.
L'extrait de Gattilier dans la composition de l'invention est de préférence un extrait liquide.  The Chasteberry extract in the composition of the invention is preferably a liquid extract.
Ledit extrait liquide peut être obtenu selon le procédé d'extraction classique suivant :  Said liquid extract can be obtained according to the following conventional extraction method:
- extraction des baies de Gattilier, notamment des baies de Gattilier broyées, dans un solvant, tel que de l'alcool (par exemple de l'éthanol), de l'eau, ou un mélange d'eau et d'alcool (par exemple un mélange d'eau et d'éthanol),  - extraction of Chasteberry berries, including crushed Chasteberry berries, in a solvent, such as alcohol (eg ethanol), water, or a mixture of water and alcohol (eg example a mixture of water and ethanol),
- filtration des résidus (solides) de baies, pour obtenir un extrait liquide de Gattilier.  - Filtration of berry residues (solids) to obtain a liquid extract of Chasteberry.
Ledit procédé peut comprendre une étape de lavage, préalable à l'étape d'extraction. Cette étape de lavage peut être une étape consistant à laver les baies de Gattilier dans un solvant tel que de l'alcool (par exemple de l'éthanol), de l'eau, ou un mélange d'eau et d'alcool (par exemple un mélange d'eau et d'éthanol); puis à filtrer le résidu liquide (i.e. le solvant de lavage), pour obtenir des baies de Gattilier lavées.  Said method may comprise a washing step, prior to the extraction step. This washing step may be a step of washing the Chasteberry berries in a solvent such as alcohol (eg ethanol), water, or a mixture of water and alcohol (eg example a mixture of water and ethanol); and then filtering the liquid residue (i.e. the washing solvent) to obtain washed chasteberry berries.
Ledit procédé peut comprendre en outre des étapes bien connues de l'homme du métier après l'étape de filtration des résidus, telles que par exemple une étape de purification par filtration de l'extrait liquide de Gattilier. L'extrait liquide de Gattilier peut être plus ou moins dilué dans un solvant tel que de l'alcool (par exemple de l'éthanol), de l'eau, ou un mélange d'eau et d'alcool (par exemple un mélange d'eau et d'éthanol), selon les besoins de la composition selon l'invention. Said method may further comprise steps well known to those skilled in the art after the residue filtration step, such as by for example, a purification step by filtration of the liquid extract of Chasteberry. The liquid extract of Chasteberry can be more or less diluted in a solvent such as alcohol (for example ethanol), water, or a mixture of water and alcohol (for example a mixture of water and ethanol), according to the needs of the composition according to the invention.
Pour l'étape d'extraction, comme pour l'étape de dilution, on préférera utiliser un solvant du type mélange eau/alcool, comprenant majoritairement de l'eau, et de préférence 60-70% d'eau pour 40-30% d'alcool (volume à volume).  For the extraction step, as for the dilution step, it will be preferable to use a solvent of the water / alcohol mixture type, mainly comprising water, and preferably 60-70% of water for 40-30%. alcohol (volume to volume).
Dans un mode de réalisation particulier, la composition de l'invention peut comprendre en outre un premier vecteur d'encapsulation, destiné à encapsuler l'extrait de Gattilier. A titre d'exemple, ledit premier vecteur d'encapsulation peut être une cyclodextrine.  In a particular embodiment, the composition of the invention may further comprise a first encapsulation vector, intended to encapsulate the Chasteberry extract. By way of example, said first encapsulation vector may be a cyclodextrin.
La composition peut comprendre en outre un second vecteur d'encapsulation, destiné à encapsuler ledit premier vecteur d'encapsulation. A titre d'exemple, ledit second vecteur d'encapsulation peut être un liposome, tel que notamment de la lécithine.  The composition may further comprise a second encapsulation vector for encapsulating said first encapsulation vector. By way of example, said second encapsulation vector may be a liposome, such as in particular lecithin.
Les compositions conformes à la présente invention peuvent être présentées sous les formes classiquement utilisées pour une application topique, c'est-à-dire sous forme de gel, lotion, émulsion (en particulier crème ou lait), sérum (ou essence), masque ou pommade, contenant des excipients et supports usuels compatibles et pharmaceutiquement acceptables. Elles peuvent aussi se présenter sous forme de lingettes imbibées d'une solution contenant l'extrait de Gattilier selon l'invention.  The compositions in accordance with the present invention may be presented in the forms conventionally used for topical application, that is to say in the form of a gel, lotion, emulsion (in particular cream or milk), serum (or essence), mask or ointment, containing compatible and pharmaceutically acceptable excipients and common carriers. They may also be in the form of wipes soaked with a solution containing Chasteberry extract according to the invention.
Ces formes d'administration par voie topique sont préparées par des techniques bien connues de l'homme du métier, et par exemple, dans le cas d'une crème, par dispersion d'une phase grasse dans une phase aqueuse pour obtenir une émulsion huile dans eau, ou inversement pour préparer une émulsion eau dans huile.  These forms of topical administration are prepared by techniques well known to those skilled in the art, and for example, in the case of a cream, by dispersion of a fatty phase in an aqueous phase to obtain an oil emulsion. in water, or conversely to prepare a water-in-oil emulsion.
La composition selon l'invention peut comprendre un ou plusieurs excipients usuels, adaptés notamment à une administration topique externe, en particulier des excipients acceptables sur le plan dermatologique et cosmétologique. Ces excipients appropriés pour la formulation sont bien connus de l'homme du métier, et peuvent être choisis par exemple parmi un ou plusieurs des composés i à xvi listés ci-dessous: The composition according to the invention may comprise one or more usual excipients, particularly suitable for external topical administration, in particular dermatologically and cosmetologically acceptable excipients. These excipients suitable for the formulation are well known to those skilled in the art, and may be chosen for example from one or more of the compounds i to xvi listed below:
i. des vitamines antioxydantes, telles que la vitamine E, par exemple l'acétate de tocophérol ou le tocotriénol ; la vitamine C, par exemple l'ascorbyl tetraisopalmitate ; les polyphénols naturels ;  i. antioxidant vitamins, such as vitamin E, for example tocopherol acetate or tocotrienol; vitamin C, for example ascorbyl tetraisopalmitate; natural polyphenols;
ii. des vecteurs de principes actifs, tels que des cyclodextrines ; des liposomes, par exemple de la lécithine ;  ii. vectors of active ingredients, such as cyclodextrins; liposomes, for example lecithin;
iii. des huiles végétales ;  iii. vegetable oils;
iv. des gélifiant et/ou épaississants, tels que des gommes naturelles ; des polymères de synthèse ;  iv. gelling agents and / or thickeners, such as natural gums; synthetic polymers;
v. des émulsionnants et co-émulsionnants, tels que arachidyl glucoside ; cétéaryl glucoside ; behenyl alcohol ; cétéaryl alcohol ; cétostéarylique alcohol ; cétéaryl alcohol ; cetyl alcohol, steareth-2 ; steareth-21 ; isostearyl isostearate ; myristate d'isopropyl ;  v. emulsifiers and co-emulsifiers, such as arachidyl glucoside; cetearyl glucoside; behenyl alcohol; cetearyl alcohol; cetostearyl alcohol; cetearyl alcohol; cetyl alcohol, steareth-2; steareth-21; isostearyl isostearate; isopropyl myristate;
vi. des émollients et des tensioactifs, tels que octyl dodecanol ; isononyl isononanoate ; capric/caprylic triglycérides ; l'octanoate de cétéaryle ; le myristate d'isopropyle ; l'isononanoate de cétéaryle ; le 3- diisostéarate de polyglycéryle ; le polyisobutène hydrogéné ; le palmitate cétylique ; le phosphate cétylique ;  vi. emollients and surfactants, such as octyl dodecanol; isononyl isononanoate; capric / caprylic triglycerides; cetearyl octanoate; isopropyl myristate; cetearyl isononanoate; polyglyceryl 3-diisostearate; hydrogenated polyisobutene; cetyl palmitate; cetyl phosphate;
vii. des silicones tels que dimethicone, cyclomethicone ;  vii. silicones such as dimethicone, cyclomethicone;
viii. des humectants / des agents hydratants, tels que la glycérine ; le butylène glycol ; le propylène glycol ;  viii. humectants / moisturizers, such as glycerine; butylene glycol; propylene glycol;
ix. des conservateurs, tels que le phénoxyéthanol, l'acide déhydroacétique ; l'acide benzoïque ; le sorbate de potassium ; le benzoate de sodium ; des parahydroxybenzoates de méthyle, éthyle, propyle, butyle et isobutyle ;  ix. preservatives, such as phenoxyethanol, dehydroacetic acid; benzoic acid; potassium sorbate; sodium benzoate; methyl, ethyl, propyl, butyl and isobutyl parahydroxybenzoates;
x. des agents de protection contre les rayons ultraviolets, tels que des filtres solaires UV-A et UV-B hydrophiles ou lipophiles, choisis parmi la benzophénone ou un dérivé de benzophénone tel que la 2-hydroxy-4- méthoxy- benzophénone ; un ester d'acide cinnamique ; et plus particulièrement le méthoxycinnamate d'octyle, le méthoxycinnamate d' éthyl- 2-hexyle, ou encore un cyano-β, β -diphénylacrylate tel que l'octo-crylène, le 4-méthylbenzylidène camphre, et des dérivés du dibenzoylméthane tels que le 4-isopropyl dibenzoylméthane, le t-butyl-méthoxy dibenzoylméthane, et le 4- méthoxy- dibenzoylméthane ;ou tels que des pigments formant un écran UV xi. des poudres exfoliantes ; des poudres de fruits ; ou des poudres matifiantes telles que le copolymère de méthacrylate de méthyle; x. agents for protecting against ultraviolet rays, such as hydrophilic or lipophilic UV-A and UV-B sunscreens, chosen from benzophenone or a benzophenone derivative such as 2-hydroxy-4-methoxybenzophenone; a cinnamic acid ester; and more particularly octyl methoxycinnamate, 2-ethylhexyl methoxycinnamate, or a cyano-β, β-diphenylacrylate such as octo-crylene, 4-methylbenzylidene camphor, and dibenzoylmethane derivatives such as 4-isopropyl dibenzoylmethane, t-butyl-methoxy dibenzoylmethane, and 4-methoxy-dibenzoylmethane, or such as UV screen-forming pigments. exfoliating powders; fruit powders; or mattifying powders such as methyl methacrylate copolymer;
xii. des agents neutralisants ;  xii. neutralizing agents;
xiii. des solubilisants ;  xiii. solubilizers;
xiv. des colorants ;  xiv. dyes;
xv. des parfums.  xv. perfumes.
La composition selon l'invention peut en outre comprendre un ou plusieurs actifs complémentaires usuels, adaptés notamment à une administration topique externe, en particulier des actifs acceptables sur le plan dermatologique et cosmétologique.  The composition according to the invention may further comprise one or more usual complementary active agents, especially adapted for external topical administration, in particular dermatologically and cosmetologically acceptable active ingredients.
Ces actifs complémentaires appropriés pour la formulation sont bien connus de l'homme du métier, et peuvent être par exemple des actifs antiâges, des actifs apaisants, des actifs purifiants, des actifs amincissants, des actifs hydratants, ...etc  These complementary active agents suitable for the formulation are well known to those skilled in the art, and may be, for example, anti-aging active agents, soothing active agents, purifying active agents, slimming active agents, moisturizing active agents, etc.
Dans un mode de réalisation particulier, la composition de l'invention peut comprendre, en plus de l'extrait de Gattilier, une ou plusieurs vitamines antioxydantes, telles que par exemple de l'ascorbyl tetraisopalmitate et/ou du tocopherol.  In a particular embodiment, the composition of the invention may comprise, in addition to the Chasteberry extract, one or more antioxidant vitamins, such as, for example, ascorbyl tetraisopalmitate and / or tocopherol.
De préférence, l'extrait de Gattilier est vectorisé, par nanoémulsion, afin de pouvoir contrôler plus facilement la libération de l'extrait de Gattilier, et améliorer sa biodisponibilité.  Preferably, the Chasteberry extract is vectorized, by nanoemulsion, in order to be able to more easily control the release of Chasteberry extract, and improve its bioavailability.
Plus particulièrement, l'extrait de Gattilier peut être encapsulé dans un premier vecteur, tel que des cyclodextrines. Une fois l'extrait de Gattilier encapsulé dans ce premier vecteur, ce dernier peut être lui-même encapsulé dans un second vecteur, tel que des liposomes comme par exemple de la lécithine.  More particularly, the Chasteberry extract may be encapsulated in a first vector, such as cyclodextrins. Once the Chasteberry extract is encapsulated in this first vector, the latter may itself be encapsulated in a second vector, such as liposomes such as lecithin.
D'autres caractéristiques et avantages de la présente invention apparaîtront à la lumière des exemples qui vont suivre en référence à la figure unique annotée, lesdits exemples et figure étant donnés à titre illustratif et nullement limitatif. La figure 1 représente un diagramme de la production kératinocytaire de dopamine après 24 heures d'incubation en présence d'un témoin, et en présence de formulations comprenant un extrait de Gattilier. Other features and advantages of the present invention will appear in the light of the examples which follow with reference to the single annotated figure, said examples and figure being given for illustrative and not limiting. FIG. 1 represents a diagram of the keratinocyte production of dopamine after 24 hours of incubation in the presence of a control, and in the presence of formulations comprising a Chasteberry extract.
Exemples Examples
1. Evaluation de l'effet d'un extrait de Gattilier sur la production de dopamine de kératinocytes 1. Evaluation of the effect of a Chasteberry extract on keratinocyte dopamine production
Une formulation commercialement disponible a été utilisée pour évaluer l'effet d'un extrait de Gattilier sur la production de dopamine de kératinocytes humains normaux en cultures. A commercially available formulation was used to evaluate the effect of Chasteberry extract on the production of dopamine from normal human keratinocytes in cultures.
Cette formulation est le produit référencé « Happybelle-PE », commercialisée par la société Mibelle AG Biochemistry.  This formulation is the product referenced "Happybelle-PE", marketed by Mibelle AG Biochemistry.
Cette formulation comprend :  This formulation includes:
- un extrait liquide de baies de Vitex agnus-castus, comme extrait de Gattilier, cet extrait liquide est à base d'un solvant comprenant un mélange d'eau et d'éthanol (70/30 volume à volume), ledit extrait liquide comprenant 0,3 % en poids d'extrait sec de baies de a liquid extract of Vitex agnus-castus berries, such as Chasteberry extract, this liquid extract is based on a solvent comprising a mixture of water and ethanol (70/30 volume to volume), said liquid extract comprising 0.3% by weight of dry extract of berries
Gattilier, Chaste Tree,
- de la lécithine,  - lecithin,
- de la glycérine,  - glycerine,
- du tocophérol  - tocopherol
- de l'Ascorbyl Tetraisopalmitate,  - Ascorbyl Tetraisopalmitate,
- de l'huile végétale,  - vegetable oil,
- des cyclodextrines,  cyclodextrins,
- un alcool, et de  - an alcohol, and
- l'eau.  - the water.
La quantité d'extrait liquide de Gattilier dans cette formulation s'élève à environ 12,5 % en poids par rapport au poids total de la formulation. Afin de réaliser ladite évaluation, des kératinocytes humains normaux ont été obtenus à partir d'une plastie abdominale réalisée chez une femme de 66 ans. The amount of Chasteberry liquid extract in this formulation is about 12.5% by weight based on the total weight of the formulation. In order to carry out said evaluation, normal human keratinocytes were obtained from an abdominal plasty carried out in a 66-year-old woman.
Pour la réalisation des essais, ces cellules ont été cultivées jusqu'à l'obtention de monocouches confluentes.  For carrying out the tests, these cells were cultured until confluent monolayers were obtained.
Puis, les kératinocytes ont été incubés pendant 24 heures à 37 °C, sous atmosphère humide et 5 % de C02, The keratinocytes were then incubated for 24 hours at 37 ° C. under a humid atmosphere and 5% CO 2 .
- en milieu de culture seul,  - in culture medium alone,
- en milieu de culture en présence d'un produit de référence (i.e. témoin),  in the culture medium in the presence of a reference product (i.e. control),
- en milieu de culture en présence de la formulation « Happybelle-PE » à 0,01 % (v/v), et  in the culture medium in the presence of the formulation "Happybelle-PE" at 0.01% (v / v), and
- en milieu de culture en présence de la formulation « Happybelle-PE » 0,1 % (v/v).  in the culture medium in the presence of the formulation "Happybelle-PE" 0.1% (v / v).
Le milieu de culture seul est un milieu « non traité », qui ne comprend ni produit de référence, ni formulation « Happybelle-PE ».  The culture medium alone is an "untreated" medium, which does not include any reference product or "Happybelle-PE" formulation.
Le produit de référence, ou en d'autres termes le témoin, est de l'amantadine hydrochloride à 0,1 μΜ .  The reference product, or in other words the control, is amantadine hydrochloride 0.1 μΜ.
A la fin de la période d'incubation, la dopamine contenue dans les milieux d'incubation des explants a été quantifiée à l'aide d'un kit E.I.A. (« Enzyme Immuno Assay ») sensible et spécifique.  At the end of the incubation period, the dopamine contained in the explant incubation media was quantified using an E.I.A. kit. ("Enzyme Immuno Assay") sensitive and specific.
Les résultats sont rassemblés sur le diagramme de la figure 1 où l'on peut voir la production kératinocytaire de dopamine en pourcentage par rapport au témoin (100 %) :  The results are summarized in the diagram of FIG. 1, which shows the keratinocyte production of dopamine as a percentage relative to the control (100%):
- de la formulation « Happybelle-PE » à 0,01 % (v/v), et  - the formulation "Happybelle-PE" at 0,01% (v / v), and
- de la formulation « Happybelle-PE » à 0,1 % (v/v).  - the formulation "Happybelle-PE" at 0.1% (v / v).
Dans les conditions expérimentales retenues, la formulation « Happybelle-PE » est ainsi capable d'augmenter significativement la production de dopamine de kératinocytes humains normaux en culture.  Under the experimental conditions selected, the formulation "Happybelle-PE" is thus capable of significantly increasing the production of dopamine of normal human keratinocytes in culture.
Plus particulièrement, on s'aperçoit clairement sur le diagramme de la figure 1, que la production de dopamine de kératinocytes humains normaux en culture est : - 6,1 fois supérieure à celle du témoin, pour la formulation « Happybelle-PE » à 0,01 % (v/v), et More particularly, it is clear from the diagram of FIG. 1 that dopamine production of normal human keratinocytes in culture is: - 6.1 times greater than that of the control, for the formulation "Happybelle-PE" at 0.01% (v / v), and
- 6,5 fois supérieure à celle du témoin, pour la formulation « Happybelle-PE » à 0,1 % (v/v).  - 6.5 times higher than that of the control, for the formulation "Happybelle-PE" at 0.1% (v / v).
Pour note, l'amantadine hydrochloride, utilisé comme témoin, a induit une production kératinocytaire de dopamine 5 fois supérieure à celle des cellules en milieu de culture seul. L'obtention de ce résultat est considéré comme suffisante pour valider l'étude.  For note, amantadine hydrochloride, used as a control, induced keratinocyte production of dopamine 5 times greater than that of cells in culture medium alone. Obtaining this result is considered sufficient to validate the study.
Ainsi, la composition selon l'invention est efficace pour obtenir une production de dopamine par application topique, et ainsi améliorer l'état de la surface cutanée et l'homéostasie de la barrière cutanée. De ce fait, la peau s'en trouve mieux protégée, et le teint plus éclatant.  Thus, the composition according to the invention is effective for obtaining dopamine production by topical application, and thus improving the state of the cutaneous surface and the homeostasis of the cutaneous barrier. As a result, the skin is better protected, and the complexion more radiant.
2. Composition cosmétique et/ou dermatologique à base d'un extrait de Gattilier selon l'invention 2. Cosmetic and / or dermatological composition based on an extract of Chasteberry according to the invention
Dans les formulations détaillées ci-après, le produit référencé « Happybelle-PE », commercialisée par la société Mibelle AG Biochemistry, comprend environ 12,5 % en poids d'extrait liquide de Gattilier (par rapport au poids total du produit Happybelle-PE). In the formulations detailed below, the product referenced "Happybelle-PE", marketed by the company Mibelle AG Biochemistry, comprises about 12.5% by weight of liquid extract of Chasteberry (relative to the total weight of the product Happybelle-PE ).
2.1. Exemple de formulation d'un gel Suivant les techniques classiques, on prépare un gel à base d'une composition selon l'invention ayant la composition pondérale suivante : 2.1. Example of Formulation of a Gel According to conventional techniques, a gel based on a composition according to the invention having the following weight composition is prepared:
Eau Déminéralisée, q .s.p. 100,0 Demineralised water, q .s.p. 100.0
Happybelle-PE 1,0  Happybelle-PE 1.0
Gélifiant 3,0  Gelling agent 3.0
Agent neutralisant 3,0  Neutralizing Agent 3.0
Humectants 8,0  Humectants 8.0
Conservateurs 3,0 Colorants 0, 1 Conservatives 3.0 Dyes 0, 1
Parfum 0,8  Perfume 0.8
Solubilisant 3,0  Solubilizer 3.0
Actifs complémentaires 20,0  Complementary assets 20.0
2.2. Exemple de formulation d'une crème 2.2. Example of a cream formulation
Suivant les techniques classiques, on prépare une crème à base d'une composition selon l'invention ayant la composition pondérale suivante : According to conventional techniques, a cream based on a composition according to the invention having the following weight composition is prepared:
Eau Déminéralisée, q .s.p. 100,0 Demineralised water, q .s.p. 100.0
Happybelle-PE 1,0  Happybelle-PE 1.0
Gélifiant 1,0  Gelling agent 1.0
Humectant 5,0  Humectant 5.0
Conservateurs 3,0  Conservatives 3.0
Emulsionnant 5,0  Emulsifier 5.0
Co-Emulsionnant 5,0  Co-emulsifier 5.0
Emollient 10,0  Emollient 10.0
Huile végétale 10,0  Vegetable oil 10.0
Silicone 3,0  Silicone 3.0
Actifs complémentaires 20,0  Complementary assets 20.0
Colorants 0,1  0.1 dyes
Parfum 0,5  Perfume 0.5

Claims

REVENDICATIONS
Utilisation d'un extrait de Gattilier pour la préparation d'une composition cosmétique et/ou dermatologique pour stimuler la production de dopamine des tissus cutanés, afin d'améliorer la nutrition de la peau.  Use of Chasteberry extract for the preparation of a cosmetic and / or dermatological composition for stimulating the production of dopamine in cutaneous tissues, in order to improve the nutrition of the skin.
Utilisation d'un extrait de Gattilier pour la préparation d'une composition cosmétique et/ou dermatologique pour stimuler la production de dopamine des tissus cutanés, afin de protéger la peau. Use of a Chasteberry extract for the preparation of a cosmetic and / or dermatological composition for stimulating the production of dopamine in cutaneous tissues, in order to protect the skin.
Utilisation selon la revendication 1 ou 2, caractérisée en ce que l'extrait de Gattilier est un extrait de Vitex agnus-castus. Use according to claim 1 or 2, characterized in that the Chasteberry extract is an extract of Vitex agnus-castus.
Utilisation selon l'une quelconque des revendications précédentes, caractérisée en ce que l'extrait de Gattilier est obtenu à partir de baies de Gattilier. Use according to any one of the preceding claims, characterized in that the Chasteberry extract is obtained from Chasteberry berries.
Utilisation selon l'une quelconque des revendications précédentes, caractérisée en ce que l'extrait de Gattilier est un extrait liquide. Use according to any one of the preceding claims, characterized in that the Chasteberry extract is a liquid extract.
Utilisation selon l'une quelconque des revendications précédentes, caractérisée en ce que la composition comprend au plus 5 % en poids d'un extrait de Gattilier, par rapport au poids total de la composition. Use according to any one of the preceding claims, characterized in that the composition comprises at most 5% by weight of a Chasteberry extract, relative to the total weight of the composition.
Utilisation selon l'une quelconque des revendications précédentes, caractérisée en ce que la composition comprend en outre un premier vecteur d'encapsulation, destiné à encapsuler l'extrait de Gattilier. Use according to any one of the preceding claims, characterized in that the composition further comprises a first encapsulation vector for encapsulating the Chasteberry extract.
Utilisation selon la revendication 7, caractérisée en ce que le premier vecteur d'encapsulation est une cyclodextrine. Use according to claim 7, characterized in that the first encapsulation vector is a cyclodextrin.
Utilisation selon la revendication 7 ou 8, caractérisée en ce que la composition comprend en outre un second vecteur d'encapsulation, destiné à encapsuler le premier vecteur d'encapsulation. Use according to claim 7 or 8, characterized in that the composition further comprises a second encapsulation vector for encapsulating the first encapsulation vector.
10. Utilisation selon la revendication 9, caractérisée en ce que le second vecteur d'encapsulation est un liposome. 10. Use according to claim 9, characterized in that the second encapsulation vector is a liposome.
11. Utilisation selon l'une quelconque des revendications précédentes, de la composition comme application topique. 11. Use according to any one of the preceding claims, of the composition as a topical application.
12. Utilisation selon l'une quelconque des revendications précédentes, de la composition pour favoriser la reconstruction de la fonction barrière de la couche cornée. 12. Use according to any one of the preceding claims, of the composition for promoting the reconstruction of the barrier function of the stratum corneum.
13. Composition cosmétique et/ou dermatologique, caractérisée en ce qu'elle comprend un extrait de Gattilier en une quantité d'au plus 5 % en poids par rapport au poids total de la composition. 13. Cosmetic and / or dermatological composition, characterized in that it comprises a Chasteberry extract in an amount of at most 5% by weight relative to the total weight of the composition.
14. Composition cosmétique et/ou dermatologique, caractérisée en ce qu'elle comprend un extrait de Gattilier en une quantité d'au plus 2 % en poids par rapport au poids total de la composition. 14. Cosmetic and / or dermatological composition, characterized in that it comprises a Chasteberry extract in an amount of at most 2% by weight relative to the total weight of the composition.
15. Composition selon la revendication 13 ou 14, caractérisée en ce qu'elle comprend un extrait de Gattilier en une quantité d'au moins 0,006 % en poids par rapport au poids total de la composition. 15. The composition of claim 13 or 14, characterized in that it comprises a Chasteberry extract in an amount of at least 0.006% by weight relative to the total weight of the composition.
16. Composition selon la revendication 15, caractérisée en ce qu'elle comprend un extrait de Gattilier en une quantité d'au moins 0,02 % en poids par rapport au poids total de la composition. 16. Composition according to claim 15, characterized in that it comprises a Chasteberry extract in an amount of at least 0.02% by weight relative to the total weight of the composition.
EP13724551.0A 2012-05-14 2013-05-14 Use of a chaste tree extract for preparing a cosmetic and/or dermatological composition Ceased EP2849720A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR1254366A FR2990351B1 (en) 2012-05-14 2012-05-14 USE OF A GATTILIER EXTRACT FOR THE PREPARATION OF A COSMETIC AND / OR DERMATOLOGICAL COMPOSITION
PCT/EP2013/059923 WO2013171202A2 (en) 2012-05-14 2013-05-14 Use of a chaste tree extract for preparing a cosmetic and/or dermatological composition

Publications (1)

Publication Number Publication Date
EP2849720A2 true EP2849720A2 (en) 2015-03-25

Family

ID=48483045

Family Applications (1)

Application Number Title Priority Date Filing Date
EP13724551.0A Ceased EP2849720A2 (en) 2012-05-14 2013-05-14 Use of a chaste tree extract for preparing a cosmetic and/or dermatological composition

Country Status (3)

Country Link
EP (1) EP2849720A2 (en)
FR (1) FR2990351B1 (en)
WO (1) WO2013171202A2 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1980241B1 (en) * 2007-04-04 2015-10-14 Mibelle AG Wet wipes with vitex agnus castus extract for feminine personal care
CH698274B1 (en) * 2008-12-12 2009-06-30 Labo Cosprophar Ag Complex of active plant stem cells and cosmetic composition.

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FUZIWARA ET AL: "Dopamine D2-Like Receptor Agonists Accelerate Barrier Repair and Inhibit the Epidermal Hyperplasia Induced by Barrier Disruption - ScienceDirect", JOURNAL OF INVESTIGATIVE DERMATOLOGY, 1 October 2005 (2005-10-01), pages 783 - 789, XP055594302, Retrieved from the Internet <URL:https://www.sciencedirect.com/science/article/pii/S0022202X15324520> [retrieved on 20190605] *
See also references of WO2013171202A2 *

Also Published As

Publication number Publication date
FR2990351A1 (en) 2013-11-15
WO2013171202A2 (en) 2013-11-21
WO2013171202A3 (en) 2014-04-24
FR2990351B1 (en) 2014-12-19

Similar Documents

Publication Publication Date Title
CA2357862A1 (en) Use of at least one extract from at least one plant from the ericaceae family in compositions for treating skin showing signs of old age
CA2491150A1 (en) Use of isoflavones to prepare topical formulations for promoting weight loss, and associated cosmetic treatment method
FR3135899A1 (en) Cosmetic or dermatological use of a Dendrobium officinale extract to maintain and/or increase the thickness of the skin
EP3801778B1 (en) Use of a bixa orellana extract
EP2291173B1 (en) Combination of passion flower and alkanet extracts for use in cosmetics
FR3091162A1 (en) Cosmetic and / or nutraceutical use of a bark extract of Eperua falcata
EP1768684B1 (en) Composition comprising a blue lotus extract for the treatment of facial uncontrolled muscular contractions
FR2885050A1 (en) Slimming cosmetic and/or pharmaceutical composition, useful for treatment of adipocytes of skin, comprises cocoa extract containing polyphenols
EP2699227B1 (en) Plant extract complex for skin protection
EP2200432A2 (en) Antimicrobial composition that can be used in cosmetics and in dermatology
WO2015118281A1 (en) Composition for controlling hair loss
WO2013171202A2 (en) Use of a chaste tree extract for preparing a cosmetic and/or dermatological composition
EP2811978B1 (en) Use of an apple tree bark extract in a cosmetic anti-ageing composition
EP2777709B1 (en) Use of a lipophilic extract of water hyacinth for moisturising the skin
FR2876908A1 (en) Use of chaulmoogra oil, or its components, for treatment or prevention of excess fat and cellulitis, acts by inducing lipolysis
WO2014001465A2 (en) Soothing topical composition containing paeonia and nymphaea extracts
FR3099701A1 (en) New cosmetic use of a combination of oenothein-B and quercetin-3-O-glucuronide
WO2013117866A2 (en) Use of an apple tree leaf extract in a cosmetic skin-firming composition
WO2023180661A1 (en) Cosmetic or dermatological use of an extract of dendrobium officinale for maintaining and/or increasing the thickness of the skin
FR3110421A1 (en) Narcissus poeticus extract for its cosmetic use
FR2885052A1 (en) Use of a maca extract (Lepidium meyenii) for the preparation a dermatological medicament for topical use to prevent and treat the deficiency of cutaneous microcirculation
FR2885300A1 (en) Topical cosmetic and/or dermatological composition useful for skin protection comprises an araucaria seed extract
FR2885049A1 (en) Topical cosmetic and/or dermatological composition, useful to protect the skin and to fight against the climatic and environmental effect, comprises a seed extract of Araucaria
WO2013117865A2 (en) Use of an apple juice extract in a cosmetic skin-comforting composition
WO2012172200A1 (en) Composition based on samanea saman for protecting the skin

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20141120

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

AX Request for extension of the european patent

Extension state: BA ME

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20170526

REG Reference to a national code

Ref country code: DE

Ref legal event code: R003

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20190606